Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: Evaluation of their clinical relevance

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 851-858

  Apostolaki, S ^a   Perraki, M ^a   Pallis, A ^b   Bozionelou, V ^b   Agelaki, S ^b   Kanellou, P ^b   Kotsakis, A ^b   Politaki, E ^a   Kalbakis, K ^b   Kalykaki, A ^b   Vamvakas, L ^b   Georgoulias, V ^a,b   Mavroudis, D ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Adjuvant chemotherapy; CTCs; Early breast cancer; HER2 mRNA; Occult tumor cells

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INFILTRATION; CANCER MORTALITY; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447302323     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl502     Document Type: Article

References (37)

1. Lambrechts AC, van Veer LJ, Rodenhuis S. The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol 1998: 9: 1269-1276.
2. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999; 91: 1113-1124.
3. Cote RJ, Rosen PP, Lesser ML et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastatses. J Clin Oncol 1991; 9: 1749-1756.
4. Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med 2000; 342: 525-533.
5. Diel IJ, Kaufmann M, Costa SD et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-5168.
6. Mansi JL, Easton D, Berger U et al. Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-up. Eur J Cancer 1991; 27: 1552-1555.
7. Helos KK, Elfenbein GJ, Trudeau WL et al. Clinical significance of bore marrow metastases detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
8. Harbeck N, Untch M, Pache L, Eiermann W. Tumor cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up. Br J Cancer 1994; 69: 566-571.
9. Stathopoulou A, Vlachonikolis I, Mavroudis D et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J Clin Oncol 2002: 20: 3404-3412.
10. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
11. Xenidis N, Perraki M, Kafousi M et al. Predictive and prognostic value of peripheral blood cytokeratic-19 mRNA positive cells detected by real time PCR in node-negative breast cancer patients. J Clin Oncol 2006; 24(23): 3756-3762.
12. Zach O, Kasparu H, Krieger O et al. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 1999; 17: 2015-2019.
13. Luppi M, Morselli M, Bandieri E et al. Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. Ann Oncol 1996; 7: 619-624.
14. Gerhard M, Juhl H, Kalthoff H et al. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994; 12: 725-729.
15. Stathopoulou A, Mavroudis D, Perraki M et al. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res 2003; 23: 1883-1890.
16. Brandt B, Roetger A, Heidl S et al. Isolation of blood-bone epithelium-derived c-erb-B2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancr 1998; 76: 824-828.
17. Solomayer EF, Becker S, Pergolo-Becker G et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Brest Cancer Res Treat 2006: 98(2): 179-184.
18. Braun S, Schlimok G, Heumos I et al. erbB2 overexpression on occult tumor metastatic cells in bone marrow predicts poor clinical outcome of stage I-II breast cancer patients. Cancer Res 2001; 61: 1890-1892.
19. Wulfing P, Bochard J, Buerger R, et al. HER 2 positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006; 12: 1715-1720.
20. Bozionellou V, Mavroudis D, Perraki M et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004; 10: 8185-8194.
21. Wasserman L, Dreilinger A, Easter D, Wallace A. A seminested RT-PCR assay for HFR2/neu: Initial validation of a new method for the detection of disseminated breast cancer cells. Mol Diagn 1999; 4: 21-28.
22. Braun S, Kentenich C, Janni W et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in the bone marrow of high-risk breast cancer patients. J Clin Oncol 2000; 18: 80-86.
23. Xenidis N, Vlachonikolis I, Mavroudis D et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003; 14: 849-855.
24. Pantel K, Dickmanns A, Zippelius A et al: Establishment of micrometastatic carcinoma cell line: A novel source of tumor cell vaccines. J Natl Cancer Inst 1995; 87: 1162-1168.
25. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997; 3: 505-509.
26. Thomas D, Giordano T, Sanders D et al. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002; 8: 788-793.
27. Cox DR. The Analysis of Binary Data. London, UK: Methuen 1970.
28. Collett D. Modeling Binary Data. London, UK: Chapman and Hall 1999.
29. Collett D. Modeling Survival Data in Medical Research. London, UK: Chapman and Hall 1994.
30. Altman GD. Practical Statistics for Medical Research. London, UK: Chapman and Hall 1991.
31. Armitage P, Berry G. Statistical Methods in Medical Research, Third edition. Oxford, UK: Blackwell Scientific 1994.
32. Aerts J, Wynendaele W, Paridaens R et al. A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol 2001; 12: 39-46.
33. Giatromanolaki A, Koukourakis MI, Kakolyris S et al. Assessment of highly angiogenic and disseminated tumor cells in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int J Cancer 2004; 108: 620-627.
34. Stathopoulos EN, Sanidas E, Kafousi M et al. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol 2005; 16: 240-246.
35. Pantel K, Schlimok G, Braun S et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-1424.
36. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
37. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-1430.